UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 orOR 15(d) of The Securities Exchange Act of 1934

Date of ~~the~~Report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported): October 19, 2022

~~Date~~QLY ofBIOTECH ~~Report~~GROUP CORP. (~~date~~Exact name of ~~earliest~~registrant ~~event~~as ~~reported):August~~specified ~~17,~~in ~~2022~~its charter)

QLY BIOTECH GROUP CORP. (Exact Name of Registrant as Specified in its Charter)

Nevada

333-234137

98-1448750

(State or other jurisdiction of

incorporation or organization)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

Nevada	333-234137	98-1448750
5348 VEGAS DRIVE, LAS VEGAS Nevada	89108
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(Address of principal executive offices)	(Zip Code)

~~Carretera~~Registrant’s ~~Turistica,~~telephone ~~Luperon~~number, ~~12th~~including ~~km,~~area ~~No.~~code: ~~7, Grand Parada, Puerto Plata, Dominican Republic~~ (~~Address of principal executive offices~~86) ~~(Zip Code)~~18678961296

~~(829)~~Check ~~947~~the appropriate box below if the Form 8-~~5251~~K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

(Registrant’s telephone number, including area code)

Azar International Corp.

(Former Name or former address if changed from last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered under Section 12(g) of the Exchange Act: None

Securities registered pursuant to Section 12(b) of the Act: None

~~Title~~Securities ofregistered ~~each~~pursuant ~~class~~to ~~Trading~~Section ~~Symbol~~12(sg) ~~Name~~ of ~~each~~the ~~exchange on which registered N/A N/A N/A~~Act:

Item 5.03 Amendments to Articles of Incorporation or By-Laws; Change in Fiscal Year.

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $.001 par value		LQLY		N/A

OnIndicate ~~August~~by ~~17,~~check ~~2022,~~mark ~~Azar~~whether ~~International Corp. (~~the ~~“Company”),~~registrant ~~amended~~is ~~its~~an ~~articles~~emerging ofgrowth ~~incorporation~~company ~~change~~as ~~its~~defined ~~name~~in toRule ~~QLY~~405 ~~Biotech~~of ~~Group Corp. (~~the ~~“Name~~Securities ~~Change”).~~Act ~~The~~of ~~change~~1933 ~~was~~(§230.405 ~~made in anticipation~~ of ~~entering~~this ~~into~~chapter) aor ~~new~~Rule ~~line~~12b–2 of ~~business~~the ~~operations.~~Securities ~~Also~~Exchange onAct ~~August~~of ~~17,~~1934 ~~2022,~~(§ ~~the~~240.12b–2 ~~Company increased its authorized shares~~ of ~~common~~this ~~stock to 1,000,000,000~~chapter).

~~Item~~Emerging ~~8.01.~~growth ~~Other~~company ~~Events~~☐

OnIf ~~August~~an ~~23,~~emerging ~~2022~~growth company, ~~FINRA~~indicate ~~declared~~by ~~the~~check ~~Name~~mark ~~Change.~~if ~~Also~~the onregistrant ~~July~~has ~~28,~~elected ~~2022,~~not to use the ~~Company~~extended ~~was~~transition ~~informed~~period byfor ~~FINRA~~complying ~~that~~with ~~the~~any ~~Company’s~~new ~~ticker~~or ~~symbol~~revised ~~would~~financial beaccounting ~~changed~~standards provided pursuant to ~~LQLY~~Section in13(a) ~~twenty~~of ~~business~~the ~~days~~Exchange Act. ☐

Item 94.01 ~~Financial~~Changes ~~Statements~~in ~~and~~Registrant’s ~~Exhibits.~~Certifying Accountant

~~(d)~~Previous ~~Exhibits.~~Independent Accountants

3.1		Certificate of Amendment, filed with the Secretary of State of the State of Nevada on August 17, 2022.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

On October 19, 2022, the Company dismissed MICHAEL GILLESPIE & ASSOCIATES, PLLC (“Michael Gillespie & Associates”) as the Company’s independent registered public accounting firm. The decision to dismiss Michael Gillespie & Associates was approved by our Board of Directors. The Company has authorized Michael Gillespie & Associates to respond fully to the inquiries of the successor auditors.

During the interim periods from September 1, 2021 to May 31, 2022, there were no: (1) disagreements (as described in Item 304(a)(1)(iv) of Regulation S-K) with Michael Gillespie & Associates on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to their satisfaction would have caused them to make reference in connection with their opinion to the subject matter of the disagreement, or (2) reportable events (as described in Item 304(a)(1)(v) of Regulation S-K) other than the material weakness in internal control over financial reporting identified and disclosed by us in our Form 10-Q for the interim periods from September 1, 2021 to May 31, 2022.

~~SIGNATURES~~We have provided Michael Gillespie & Associates with a copy of the foregoing disclosures and have requested that Michael Gillespie & Associates provide a letter addressed to the Securities & Exchange Commission stating whether it agrees with the disclosure contained herein and, if not, stating the respects in which it does not agree. Pursuant to our request, Michael Gillespie & Associates has provided the letter attached hereto as Exhibit 16.1.

~~Pursuant~~New toIndependent ~~the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~ Accountants

On October 1119, 2022, our Board of Directors appointed TAAD LLP of Diamond Bar, California (“TAAD”) as our independent registered public accounting firm, to audit our financial statements for the year ended August 31, 2022. During our two most recent fiscal years and the subsequent interim periods preceding their appointment as independent accountants, neither we nor anyone on our behalf consulted TAAD regarding either the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered of our financial statements, nor has TAAD provided to us with a written report or oral advice regarding such principles or audit opinion.

~~QLY~~Item ~~BIOTECH GROUP CORP~~9.01 ~~/s/~~Financial ~~Yang,~~statements ~~Lixue~~and ~~By: YANG, LIXUE Title: CEO~~Exhibits

Exhibit Number		Exhibit Description
16.1		Letter to SEC from MICHAEL GILLESPIE & ASSOCIATES, PLLC
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	QLY BIOTECH GROUP CORP.

Dated: October 19, 2022	By:	/s/ YANG LIXUE
	Name:	Yang Lixue
	Title:	Chief Executive Officer, President and Secretary

Filing Compare · QLY Biotech Group Corp.